Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NVCR 
Novocure Ltd (NVCR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: NVCR (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
7 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Year Target Price $32.57
Year Target Price $32.57
| 3 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.8% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.01B USD | Price to earnings Ratio - | 1Y Target Price 32.57 |
Price to earnings Ratio - | 1Y Target Price 32.57 | ||
Volume (30-day avg) 7 | Beta 0.75 | 52 Weeks Range 14.17 - 34.13 | Updated Date 06/30/2025 |
52 Weeks Range 14.17 - 34.13 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.51 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-06-05 | When Before Market | Estimate -0.464 | Actual -0.31 |
Profitability
Profit Margin -26.41% | Operating Margin (TTM) -24.43% |
Management Effectiveness
Return on Assets (TTM) -8.64% | Return on Equity (TTM) -45.52% |
Valuation
Trailing PE - | Forward PE 909.09 | Enterprise Value 1775455268 | Price to Sales(TTM) 3.23 |
Enterprise Value 1775455268 | Price to Sales(TTM) 3.23 | ||
Enterprise Value to Revenue 2.86 | Enterprise Value to EBITDA -6.92 | Shares Outstanding 111486000 | Shares Floating 100768520 |
Shares Outstanding 111486000 | Shares Floating 100768520 | ||
Percent Insiders 9.87 | Percent Institutions 87.4 |
Analyst Ratings
Rating 3 | Target Price 32.57 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Novocure Ltd
Company Overview
History and Background
Novocure Ltd. was founded in 2000 in Haifa, Israel. It is a global oncology company pioneering a novel therapy called Tumor Treating Fields (TTFields) for solid tumors. Novocure began focusing on glioblastoma (GBM) and has expanded to other cancers.
Core Business Areas
- Tumor Treating Fields (TTFields) Therapy: This is Novocure's core technology, a non-invasive cancer therapy that uses electric fields to disrupt cancer cell division.
Leadership and Structure
Novocure is led by a management team headed by the CEO. The company has a board of directors overseeing strategic direction and governance.
Top Products and Market Share
Key Offerings
- Optune (TTFields for Glioblastoma): Optune is Novocure's primary product, a device that delivers TTFields to treat glioblastoma. Its competitors include standard-of-care treatments like surgery, chemotherapy, and radiation. No specific market share data available, but they are a major player in TTFields and growing in GBM treatment.
Market Dynamics
Industry Overview
The oncology market is large and growing, driven by an aging population and advancements in cancer treatments. There is a push towards targeted therapies.
Positioning
Novocure occupies a unique position with its TTFields technology, offering a non-invasive treatment option. Its competitive advantage lies in this unique approach to disrupting cancer cell growth.
Total Addressable Market (TAM)
The TAM for cancer therapies is estimated to be in the hundreds of billions of dollars. Novocure is positioned to capture a portion of this market through the expansion of TTFields therapy to other cancers.
Upturn SWOT Analysis
Strengths
- Novel Technology (TTFields)
- Clinically Proven Efficacy in Glioblastoma
- Expanding into Other Cancer Types
- Strong Patent Protection
- Non-invasive treatment option
Weaknesses
- High Cost of Therapy
- Limited Number of Approved Indications
- Patient Compliance with Device Usage
- Need for more Clinical Evidence on the effectiveness of TTFields in other cancer types.
Opportunities
- Expanding Indications for TTFields Therapy (e.g., lung cancer, ovarian cancer)
- Partnerships with Pharmaceutical Companies
- Geographic Expansion
- Developing new TTFields devices for other cancers
Threats
- Competition from Established Cancer Therapies
- Regulatory Hurdles
- Reimbursement Challenges
- Negative clinical trial outcomes in new indications
- Potential for generic competition after patent expiration
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
- AZN
Competitive Landscape
Novocure's TTFields technology offers a unique approach compared to traditional therapies like chemotherapy and radiation, giving it a competitive edge in certain patient populations. However, it faces challenges from well-established pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Novocure's historical growth has been driven by the adoption of Optune for GBM and the pursuit of new indications.
Future Projections: Analyst projections would be needed to specify future growth forecasts.
Recent Initiatives: Recent initiatives include clinical trials for new cancer types and efforts to improve patient compliance with Optune.
Summary
Novocure is a company with an innovative cancer therapy that is growing rapidly. They have a unique treatment that shows success in certain areas, however, it faces limitations with costs and patient compliance. They need to continue to expand indications and improve their offerings while also watching out for regulatory hurdles and well-established competitors. The company's long term survival depends on the continual pursuit of cancer treatments through device delivery.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Novocure Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-10-02 | CEO & Director Ms. Ashley Cordova | ||
Sector Healthcare | Industry Medical Devices | Full time employees 1488 | Website https://www.novocure.com |
Full time employees 1488 | Website https://www.novocure.com | ||
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.